
Vascular endothelial growth inhibitor - Wikipedia
Vascular endothelial growth inhibitor (VEGI), also known as TNF-like ligand 1A (TL1A) and TNF superfamily member 15 (TNFSF15), is protein that in humans is encoded by the TNFSF15 …
TL1A: Exploring a potentially important target for inflammatory
2024年10月9日 · TL1A is a cytokine, a protein functioning as a chemical messenger, that acts as a regulator of cellular immunity. In healthy people, levels of TL1A increase to help immune …
Teva, Sanofi score well with anti-TL1A drug in IBD test
4 天之前 · Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease …
Frontiers | TL1A (TNFSF15) and DR3 (TNFRSF25): A Co-stimulatory …
2019年3月26日 · TL1A is a type II transmembrane protein with a molecular weight of 28 kDa, which contains 251 amino acids. Similar to other members of the TNF-family, TL1A forms a …
TL1A Pathway: Embarking on New Frontiers in IBD Therapy with …
TL1A (TNF-like cytokine 1A), encoded by the TNFSF15 gene, is a member of the TNF superfamily. By binding to death receptor 3 (DR3), TL1A activates pathways involved in cell …
TL1A:DR3 - A Pathway for Immunomodulation - BPS Bioscience
TL1A bridges innate and adaptive immune responses and is a key driver of autoimmune and inflammatory pathologies, including Crohn’s Disease (CD), rheumatoid arthritis (RA), …
TL1A: How It Shapes Mucosal Immunity and Chronic Inflammation
2025年3月11日 · TL1A is a key regulator of immune responses, particularly in mucosal tissues, where it influences both protective immunity and inflammatory diseases. By modulating T cell …
Targeting TL1A and DR3: the new frontier of anti-cytokine therapy …
TL1A and DR3 are expressed by cellular subsets with important roles for the initiation and maintenance of intestinal inflammation, serving as potent universal costimulators of effector …
TL1A Inhibition in Inflammatory Bowel Disease: A Pipeline Review
2025年2月5日 · TL1A, a TNF superfamily member, is implicated in IBD pathogenesis through its effects on inflammation and fibrosis. It promotes T-cell activation and interacts with death …
A New Target to Transform IBD Treatment - Sanofi
2025年2月26日 · Targeting the TL1A pathway has shown great promise as a potential mechanism for addressing IBD symptoms by reducing inflammation in the digestive tract of people with UC …